Alembic Pharmaceuticals Limited

NSEI:APLLTD Stock Report

Market Cap: ₹173.6b

Alembic Pharmaceuticals Management

Management criteria checks 3/4

Alembic Pharmaceuticals' CEO is Chirayu Amin, appointed in Apr 2016, has a tenure of 8.17 years. total yearly compensation is ₹88.00M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.13% of the company’s shares, worth ₹3.70B. The average tenure of the management team and the board of directors is 8.2 years and 10.2 years respectively.

Key information

Chirayu Amin

Chief executive officer

₹88.0m

Total compensation

CEO salary percentage100.0%
CEO tenure8.2yrs
CEO ownership2.1%
Management average tenure8.2yrs
Board average tenure10.2yrs

Recent management updates

Recent updates

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Jun 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

May 11
Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08
Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Jan 21
Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Jan 05
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Sep 27
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Jun 09
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Apr 13
A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Feb 22
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jan 04
Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Aug 10
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Jul 20
Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

May 05
We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Jan 17
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?

Dec 17
Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?

These 4 Measures Indicate That Alembic Pharmaceuticals (NSE:APLLTD) Is Using Debt Reasonably Well

Sep 23
These 4 Measures Indicate That Alembic Pharmaceuticals (NSE:APLLTD) Is Using Debt Reasonably Well

Is There An Opportunity With Alembic Pharmaceuticals Limited's (NSE:APLLTD) 27% Undervaluation?

Sep 02
Is There An Opportunity With Alembic Pharmaceuticals Limited's (NSE:APLLTD) 27% Undervaluation?

CEO Compensation Analysis

How has Chirayu Amin's remuneration changed compared to Alembic Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

₹6b

Dec 31 2023n/an/a

₹6b

Sep 30 2023n/an/a

₹5b

Jun 30 2023n/an/a

₹5b

Mar 31 2023₹88m₹88m

₹3b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹3b

Jun 30 2022n/an/a

₹3b

Mar 31 2022₹280m₹80m

₹5b

Dec 31 2021n/an/a

₹8b

Sep 30 2021n/an/a

₹9b

Jun 30 2021n/an/a

₹10b

Mar 31 2021₹315m₹65m

₹11b

Dec 31 2020n/an/a

₹12b

Sep 30 2020n/an/a

₹11b

Jun 30 2020n/an/a

₹10b

Mar 31 2020₹265m₹65m

₹8b

Dec 31 2019n/an/a

₹7b

Sep 30 2019n/an/a

₹7b

Jun 30 2019n/an/a

₹6b

Mar 31 2019₹255m₹55m

₹6b

Dec 31 2018n/an/a

₹6b

Sep 30 2018n/an/a

₹5b

Jun 30 2018n/an/a

₹4b

Mar 31 2018₹220m₹55m

₹4b

Compensation vs Market: Chirayu's total compensation ($USD1.05M) is above average for companies of similar size in the Indian market ($USD444.28K).

Compensation vs Earnings: Chirayu's compensation has been consistent with company performance over the past year.


CEO

Chirayu Amin (78 yo)

8.2yrs

Tenure

₹88,000,000

Compensation

Mr. Chirayu Ramanbhai Amin, M.B.A. (U.S.A.), has been Chief Executive Officer of Alembic Pharmaceuticals Limited since April 27, 2016. Mr. Amin served as Managing Director of Alembic Pharmaceuticals Limite...


Leadership Team

NamePositionTenureCompensationOwnership
Chirayu Amin
Executive Chairman & CEO8.2yrs₹88.00m2.13%
₹ 3.7b
Pranav Amin
MD & Executive Director9.2yrs₹122.20m0.59%
₹ 1.0b
Shaunak Amin
MD & Executive Director9.2yrs₹122.20m0.51%
₹ 889.2m
Raj Kumar Baheti
Director of Financeno data₹56.90mno data
Vinod Kamath
President of Operationsno datano datano data
J. Raman
Chief Scientific Officerno data₹8.41mno data
Manisha Saraf
Company Secretary & Compliance Officer1.2yrsno datano data
Udit Amin
Chief Business Development Officerno data₹8.30m0.51%
₹ 889.1m
Gautam Chatterjee
Senior Vice Presidentno data₹8.12mno data
Ajay Desai
Senior Vice President of Financeno data₹9.20mno data
Shreekumar Nair
Senior Vice President of Supply Chainno datano datano data
Nilesh Wadhwa
Head of International Business & Strategyless than a yearno datano data

8.2yrs

Average Tenure

63yo

Average Age

Experienced Management: APLLTD's management team is seasoned and experienced (8.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Chirayu Amin
Executive Chairman & CEO14yrs₹88.00m2.13%
₹ 3.7b
Pranav Amin
MD & Executive Director13.3yrs₹122.20m0.59%
₹ 1.0b
Shaunak Amin
MD & Executive Director11.1yrs₹122.20m0.51%
₹ 889.2m
Raj Kumar Baheti
Director of Finance14yrs₹56.90mno data
Archana Hingorani
Independent Non-Executive Director9.3yrs₹1.83mno data
Manish Kejriwal
Independent Directorless than a yearno datano data
Ashok Barat
Independent Director2.3yrs₹1.82mno data
Jai Diwanji
Additional Independent Director1.1yrsno datano data

10.2yrs

Average Tenure

57.5yo

Average Age

Experienced Board: APLLTD's board of directors are seasoned and experienced ( 10.2 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.